CAR T – cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T – cell therapy .
That was three years ago, and the cancer still hasn’ t returned. The CAR T – cell therapy success rate is about 30% to 40% for lasting remission, with no additional treatment , according to Michael Bishop, MD, director of UChicago Medicine’s cellular therapy program.
Currently, CAR T-cell therapy is FDA approved as standard of care for some forms of aggressive, relapsed or refractory non-Hodgkin lymphoma including diffuse large B cell lymphoma , primary mediastinal B-cell lymphoma , high grade B-cell lymphoma , transformed follicular lymphoma , and mantle cell lymphoma .
Other serious side effects include neurotoxicity or changes in the brain that cause swelling, confusion, seizures, or severe headaches. One other problem is that the CAR T cells can kill off some of the good B cells that help fight germs, so the patient may be at higher risk for infection.
Infusion: The infusion of CAR -T cells typically takes 30 to 90 minutes . However, plan for the infusion visit to take up to six hours to allow for care before and after the infusion.
By some estimates, CAR T-cell therapy can cost as much as $375,000 for a one-time treatment, depending upon the cancer type and treatment regimen. That estimate does not include hospital stays and other related expenses.
CAR T manufacturing, changes in tumor microenvironment, previous treatments or the effects of neighbouring cells can cause ‘ CAR T cell exhaustion’. Data indicate that ‘exhausted’ CAR T cells are not as proliferative or potent as their ‘non-exhausted’ counterparts.
Since the cells can persist in the body long – term , they will still recognize and attack cancer cells if and when there’s a relapse. The data is still evolving, but after 15 months, 42% of adult lymphoma patients who received CD19 CAR T – cell therapy were still in remission.
CAR – T clinical trials have shown huge remission rates, of up to 94%, in severe forms of blood cancer. This is particularly impressive considering most CAR – T clinical trials recruit cancer patients that have not responded to many if not all other available treatments .
CAR T – cell therapy is only approved to treat two groups of people with certain types of cancer: Children and young adults up to age 25 with precursor B- cell acute lymphoblastic leukemia (ALL) that hasn’ t gotten better with treatment or that’s come back after treatment.
Medicare will cover CAR T – cell therapies when they are provided in healthcare facilities enrolled in the FDA risk evaluation and mitigation strategies (REMS) for FDA-approved indications (according to the FDA-approved label).
Chimeric antigen receptor ( CAR )- T cell therapy , also known as CAR – T cell therapy , was approved by the Food and Drug Administration in October 2017. CAR – T cell therapy is not the same as stem cell transplant or chemotherapy.
The most commonly observed CAR T – cell –associated toxicity is CRS. Fever is usually the first symptom of CRS. The time of onset of fever can be quite variable, ranging from a few hours to more than a week after CAR T – cell infusion.
As of September 2019, the U.S. Food and Drug Administration has approved two CAR T cell therapies for the treatment of cancer patients.
Costs of follow-up amounted to $4,167. Relapse treatment, mainly consisting of reinduction therapy, costs on average $24,338 . The total average weighted costs of AML patients amounted to $104,386 . Treating AML patients is very expensive, and major reductions in costs are not expected in the next future.